TPIDB > 臨床試驗主持人
臨床試驗主持人
更新時間：2026-07-18
高小雯Kao, Hsiao-Wen
- 計畫主持人
- 執行臨床試驗年資 15 年
-
hsiaowen@cgmh.org.tw
發表文獻
1筆
1
1. Pei S-N, Chen CG-S, Kao H-W, Tzeng H-E, Huang M-L, Chen C-C, Wang JH-W, Yu LH-L, Hou H-A. High-Initial-Dose Accelerated Titration Regimen of Ropeginterferon alfa-2b in Younger Patients with Polycythemia Vera and Essential Thrombocythemia: A Consecutive Case Series Study. Hemato. 2026;7(1):2.
2. Chen HC, Kao HW, Ou JH, Sun PL. Breakthrough invasive fusariosis under posaconazole prophylaxis in a neutropenic lymphoma patient. J Microbiol Immunol Infect. 2026.
3. Kao HW, Chang H, Kuo MC, Wu JH, Huang YJ, Huang TY, Lin TH, Shih LY. Genetic evolution of myeloproliferative neoplasms from chronic phase to blastic phase: An analysis of 46 paired samples. Cancer. 2025;131(16):e70048.
4. Kao HW, Kuo MC, Ou CW, Huang TY, Chang H, Lin TL, Hung YS, Wu JH, Shih LY. Clonal dynamics of chronic myelomonocytic leukemia progression: paired-sample comparison. J Pathol. 2025;265(4):437-47.
5. Tsai WC, Jung SM, Kao HW, Chang YH, Liao YL, Tsai YJ, Chu YC, Hsiao CH. Association of Chlamydia species with ocular adnexal mucosa-associated lymphoid tissue lymphoma in Taiwan. Br J Ophthalmol. 2025:bjo-2025-328028.
6. Lin ZC, Wang MC, Lin TL, Kuo MC, Kao HW, Chang H, Hung YS, Ma MC, Ong YC, Ou CW, Kuo CY, Chen YY, Huang YM, Shih HJ. Novel therapeutic agents and intensive chemotherapy improve survival outcomes in patients with mantle cell lymphoma. Am J Cancer Res. 2025;15(12):5349-63.
7. Huang YJ, Liu HC, Kuo MC, Yeh TC, Lin TL, Chen SH, Jaing TH, Wang SC, Chang TK, Yen HJ, Sheen JM, Wang MC, Lin TH, Huang TY, Kao HW, Ou CW, Hung YS, Hsiao CC, Shih LY. Frequency and prognostic value of unconventional genetic subtypes in paediatric and young adult B-cell precursor acute lymphoblastic leukaemia in Taiwan. Br J Haematol. 2025;206(6):1699-709.
8. Huang YJ, Lim JQ, Hsu JS, Kuo MC, Wang PN, Kao HW, Wu JH, Chen CC, Tsai SF, Ong CK, Shih LY. Next-Generation Integrated Sequencing Identifies Poor Prognostic Factors in Patients with MYD88-Mutated Chronic Lymphocytic Leukemia in Taiwan. Pathobiology. 2025;92(2):77-89.
9. Huang SW, Chang KW, Chen WH, Chou PL, Chiu CH, Liu YH, Wang CW, Kao HW, Lin TL, Leu SW, Hu HC, Kao KC. Multiple Myeloma Complicated With Bronchiolitis Obliterans Syndrome After Allogeneic Haematopoietic Stem Cell Transplantation and Subsequently Underwent Lung Transplantation Successfully: A Case Report. Respirol Case Rep. 2025;13(3):e70120.
10. Hou CH, Chang H, Ong YC, Kuo MC, Kao HW, Lee HL. Risk factors and clinical consequences of rituximab infusion-related reactions. Medicine (Baltimore). 2025;104(26):e42972.
11. Chuang CH, Kuo MC, Wu JH, Lin TL, Wang PN, Chang YS, Lin TH, Huang TY, Hung YS, Kao HW, Ou CW, Chang H, Shih LY. Features and Allele Frequency of JAK2 Exon 12-Mutated Polycythemia Vera in Comparison with JAK2V617F-Mutated Disease. Arch Med Res. 2025;56(2):103109.
12. Chan CY, Lin TL, Kuo MC, Hung YS, Chang H, Ou CW, Wu JH, Shih HJ, Su YJ, Shih LY, Ong YC, Chuang WY, Kao HW*. Prognostic impact of pre-treatment and post-treatment plasma Epstein-Barr virus DNA in peripheral T-cell lymphomas. Ann Med. 2025;57(1):2478315.
13. Shih HJ, Kuo MC, Lin TL, Kao HW, Wu JH, Hung YS, Ou CW, Su YJ, Chang H. Major impact of prognosis by age and sex in patients with primary mediastinal large B‑cell lymphoma. Oncol Lett. 2024;27(2):57.
14. Hsu YT, Wu SJ, Kao HW, Hsiao SY, Liao CK, Chen TY, Wang MC. Glofitamab as a salvage treatment for B-cell lymphomas in the real world: A multicenter study in Taiwan. Cancer. 2024.
15. Chen NC, Chang H, Kuo MC, Lin TL, Shih LY, Chuang WY, Kao HW*. Predictive model for treatment outcomes of peripheral T-cell lymphoma, not otherwise specified, in Taiwanese patients. J Formos Med Assoc. 2024;123(2):188-97.
16. Chan CY, Ou CW, Chang H, Kuo MC, Lin TL, Hung YS, Wu JH, Shih LY, Kao HW*. Primary breast diffuse large B-cell lymphoma characterized by CNS relapse and successful hematopoietic stem cell transplantation salvage therapy. J Formos Med Assoc. 2024;123(10):1078-86.
17. Chuang WY, Chang H, Shih LY, Lin TC, Yeh CJ, Ueng SH, Kuo MC, Kao HW, Liu H, Chang ST, Lee CL, Huang KP, Wang TH, Wan YL, Yu JS, Hsueh C, Chuang SS. Identification of CD5/SOX11 double-negative pleomorphic mantle cell lymphoma. Virchows Arch. 2024;485(2):323-34.
18. Chuang CH, Kuo MC, Chang H, Wu JH, Hung YS, Ou CW, Lin TL, Su YJ, Ong YC, Shih LY, Kao HW*. Different patterns of failure in two treatment regimens for primary central nervous system lymphoma, a retrospective analysis of 124 cases in Taiwan. Clin Exp Med. 2023;23(8):5327-36.
19. Chen NC, Chang H, Kao HW, Ou CW, Kuo MC, Wang PN, Lin TL, Wu JH, Hung YS, Su YJ, Ong YC, Shih HJ. Beta2-microglobulin is a valuable marker and identifies a poor-prognosis subgroup among intermediate-risk patients with diffuse large B cell lymphoma. Clin Exp Med. 2023;23(7):3759-66.
20. Kao HW, Kuo MC, Huang YJ, Chang H, Hu SF, Huang CF, Hung YS, Lin TL, Ou CW, Lien MY, Wu JH, Chen CC, Shih LY. Measurable Residual Disease Monitoring by Locked Nucleic Acid Quantitative Real-Time PCR Assay for IDH1/2 Mutation in Adult AML. Cancers (Basel). 2022;14(24).
21. Wang CW, Chi MH, Tsai TF, Yu KH, Kao HW, Chen HC, Chen CB, Lu CW, Chen WT, Chang YC, Chang CJ, Chang YT, Jan Wu YJ, Chang CJ, Huang YH, Ng CY, Huang PW, Lin YJ, Hui RC, Chung WH. Implementation of NUDT15 Genotyping to Prevent Azathioprine-Induced Leukopenia for Patients With Autoimmune Disorders in Chinese Population. Clin Pharmacol Ther. 2022;112(5):1079-87.
22. Tsai HJ, Hsiao HH, Hsu YT, Liu YC, Kao HW, Liu TC, Cho SF, Feng X, Johnston A, Bomalaski JS, Kuo MC, Chen TY. Phase I study of ADI-PEG20 plus low-dose cytarabine for the treatment of acute myeloid leukemia. Cancer Med. 2021;10(9):2946-55.
23. Ong YC, Kao HW, Chuang WY, Hung YS, Lin TL, Chang H, Kuo MC. Intravascular Large B-cell lymphoma: A case series and review of literatures. Biomed J. 2021;44(4):479-88.
24. Chuang WY, Chang ST, Yuan CT, Chang GJ, Chang H, Yeh CJ, Ueng SH, Kao HW, Wang TH, Wan YL, Shih LY, Chuang SS, Hsueh C. Identification of CD5/Cyclin D1 Double-negative Pleomorphic Mantle Cell Lymphoma: A Clinicopathologic, Genetic, and Gene Expression Study. Am J Surg Pathol. 2020;44(2):232-40.
25. Chou WC, Chang H, Wang PN, Kuo MC, Wu JH, Lin TL, Su YJ, Kao HW, Ou CW, Hung CY, Hsueh SW, Hung YS. Application of comprehensive geriatric assessment in predicting early mortality among elder patients with B-cell lymphoma receiving immunochemotherapy. Eur J Haematol. 2020;105(4):399-407.
26. Su YJ, Wang PN, Chang H, Shih LY, Lin TL, Kuo MC, Chuang WY, Wu JH, Tang TC, Hung YS, Dunn P, Kao HW*. Extranodal NK/T-cell lymphoma, nasal type: Clinical features, outcome, and prognostic factors in 101 cases. Eur J Haematol. 2018;101(3):379-88.
27. Huang YJ, Coustan-Smith E, Kao HW, Liu HC, Chen SH, Hsiao CC, Yang CP, Jaing TH, Yeh TC, Kuo MC, Lai CL, Chang CH, Campana D, Liang DC, Shih LY. Concordance of two approaches in monitoring of minimal residual disease in B-precursor acute lymphoblastic leukemia: Fusion transcripts and leukemia-associated immunophenotypes. J Formos Med Assoc. 2017;116(10):774-81.
28. Kao HW, Lin TL, Shih LY, Dunn P, Kuo MC, Hung YS, Wu JH, Tang TC, Chang H, Kuo TT, Ou CW, Wang PN. Clinical features, outcome and prognostic factors of 87 patients with angioimmunoblastic T cell lymphoma in Taiwan. Int J Hematol. 2016;104(2):256-65.
29. Lee MH, Lin YC, Cheng HT, Chuang WY, Huang HC, Kao HW. Coexistence of hepatoma with mantle cell lymphoma in a hepatitis B carrier. World J Gastroenterol. 2015;21(45):12981-6.
30. Kao HW, Liang DC, Kuo MC, Wu JH, Dunn P, Wang PN, Lin TL, Shih YS, Liang ST, Lin TH, Lai CY, Lin CH, Shih LY. High frequency of additional gene mutations in acute myeloid leukemia with MLL partial tandem duplication: DNMT3A mutation is associated with poor prognosis. Oncotarget. 2015;6(32):33217-25.
31. Lin TL, Nagata Y, Kao HW, Sanada M, Okuno Y, Huang CF, Liang DC, Kuo MC, Lai CL, Lee EH, Shih YS, Tanaka H, Shiraishi Y, Chiba K, Lin TH, Wu JH, Miyano S, Ogawa S, Shih LY. Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations. Haematologica. 2014;99(1):28-36.
32. Kao HW, Liang DC, Wu JH, Kuo MC, Wang PN, Yang CP, Shih YS, Lin TH, Huang YH, Shih LY. Gene mutation patterns in patients with minimally differentiated acute myeloid leukemia. Neoplasia. 2014;16(6):481-8.
33. Huang YM, Shih LY, Dunn P, Wang PN, Kuo MC, Wu JH, Lin TL, Tang TC, Chang H, Kao HW, Shih HJ, Hung YS. Chronic lymphocytic leukemia presenting with ascites diagnosed by clonality analysis via gene rearrangement assay: A case report. Oncol Lett. 2014;7(6):1911-4.
34. Kao HW, Sanada M, Liang DC, Lai CL, Lee EH, Kuo MC, Lin TL, Shih YS, Wu JH, Huang CF, Ogawa S, Shih LY. A high occurrence of acquisition and/or expansion of C-CBL mutant clones in the progression of high-risk myelodysplastic syndrome to acute myeloid leukemia. Neoplasia. 2011;13(11):1035-42.
35. Kao HW, Dunn P, Kuo MC, Shih LY, Lin TL, Wu JH, Tang TC, Chang H, Wu HC, Hung YS. Classical hairy cell leukemia and its variant: a 17-year retrospective survey in Taiwan Chinese. Acta Haematol. 2011;126(3):186-93.
2. Chen HC, Kao HW, Ou JH, Sun PL. Breakthrough invasive fusariosis under posaconazole prophylaxis in a neutropenic lymphoma patient. J Microbiol Immunol Infect. 2026.
3. Kao HW, Chang H, Kuo MC, Wu JH, Huang YJ, Huang TY, Lin TH, Shih LY. Genetic evolution of myeloproliferative neoplasms from chronic phase to blastic phase: An analysis of 46 paired samples. Cancer. 2025;131(16):e70048.
4. Kao HW, Kuo MC, Ou CW, Huang TY, Chang H, Lin TL, Hung YS, Wu JH, Shih LY. Clonal dynamics of chronic myelomonocytic leukemia progression: paired-sample comparison. J Pathol. 2025;265(4):437-47.
5. Tsai WC, Jung SM, Kao HW, Chang YH, Liao YL, Tsai YJ, Chu YC, Hsiao CH. Association of Chlamydia species with ocular adnexal mucosa-associated lymphoid tissue lymphoma in Taiwan. Br J Ophthalmol. 2025:bjo-2025-328028.
6. Lin ZC, Wang MC, Lin TL, Kuo MC, Kao HW, Chang H, Hung YS, Ma MC, Ong YC, Ou CW, Kuo CY, Chen YY, Huang YM, Shih HJ. Novel therapeutic agents and intensive chemotherapy improve survival outcomes in patients with mantle cell lymphoma. Am J Cancer Res. 2025;15(12):5349-63.
7. Huang YJ, Liu HC, Kuo MC, Yeh TC, Lin TL, Chen SH, Jaing TH, Wang SC, Chang TK, Yen HJ, Sheen JM, Wang MC, Lin TH, Huang TY, Kao HW, Ou CW, Hung YS, Hsiao CC, Shih LY. Frequency and prognostic value of unconventional genetic subtypes in paediatric and young adult B-cell precursor acute lymphoblastic leukaemia in Taiwan. Br J Haematol. 2025;206(6):1699-709.
8. Huang YJ, Lim JQ, Hsu JS, Kuo MC, Wang PN, Kao HW, Wu JH, Chen CC, Tsai SF, Ong CK, Shih LY. Next-Generation Integrated Sequencing Identifies Poor Prognostic Factors in Patients with MYD88-Mutated Chronic Lymphocytic Leukemia in Taiwan. Pathobiology. 2025;92(2):77-89.
9. Huang SW, Chang KW, Chen WH, Chou PL, Chiu CH, Liu YH, Wang CW, Kao HW, Lin TL, Leu SW, Hu HC, Kao KC. Multiple Myeloma Complicated With Bronchiolitis Obliterans Syndrome After Allogeneic Haematopoietic Stem Cell Transplantation and Subsequently Underwent Lung Transplantation Successfully: A Case Report. Respirol Case Rep. 2025;13(3):e70120.
10. Hou CH, Chang H, Ong YC, Kuo MC, Kao HW, Lee HL. Risk factors and clinical consequences of rituximab infusion-related reactions. Medicine (Baltimore). 2025;104(26):e42972.
11. Chuang CH, Kuo MC, Wu JH, Lin TL, Wang PN, Chang YS, Lin TH, Huang TY, Hung YS, Kao HW, Ou CW, Chang H, Shih LY. Features and Allele Frequency of JAK2 Exon 12-Mutated Polycythemia Vera in Comparison with JAK2V617F-Mutated Disease. Arch Med Res. 2025;56(2):103109.
12. Chan CY, Lin TL, Kuo MC, Hung YS, Chang H, Ou CW, Wu JH, Shih HJ, Su YJ, Shih LY, Ong YC, Chuang WY, Kao HW*. Prognostic impact of pre-treatment and post-treatment plasma Epstein-Barr virus DNA in peripheral T-cell lymphomas. Ann Med. 2025;57(1):2478315.
13. Shih HJ, Kuo MC, Lin TL, Kao HW, Wu JH, Hung YS, Ou CW, Su YJ, Chang H. Major impact of prognosis by age and sex in patients with primary mediastinal large B‑cell lymphoma. Oncol Lett. 2024;27(2):57.
14. Hsu YT, Wu SJ, Kao HW, Hsiao SY, Liao CK, Chen TY, Wang MC. Glofitamab as a salvage treatment for B-cell lymphomas in the real world: A multicenter study in Taiwan. Cancer. 2024.
15. Chen NC, Chang H, Kuo MC, Lin TL, Shih LY, Chuang WY, Kao HW*. Predictive model for treatment outcomes of peripheral T-cell lymphoma, not otherwise specified, in Taiwanese patients. J Formos Med Assoc. 2024;123(2):188-97.
16. Chan CY, Ou CW, Chang H, Kuo MC, Lin TL, Hung YS, Wu JH, Shih LY, Kao HW*. Primary breast diffuse large B-cell lymphoma characterized by CNS relapse and successful hematopoietic stem cell transplantation salvage therapy. J Formos Med Assoc. 2024;123(10):1078-86.
17. Chuang WY, Chang H, Shih LY, Lin TC, Yeh CJ, Ueng SH, Kuo MC, Kao HW, Liu H, Chang ST, Lee CL, Huang KP, Wang TH, Wan YL, Yu JS, Hsueh C, Chuang SS. Identification of CD5/SOX11 double-negative pleomorphic mantle cell lymphoma. Virchows Arch. 2024;485(2):323-34.
18. Chuang CH, Kuo MC, Chang H, Wu JH, Hung YS, Ou CW, Lin TL, Su YJ, Ong YC, Shih LY, Kao HW*. Different patterns of failure in two treatment regimens for primary central nervous system lymphoma, a retrospective analysis of 124 cases in Taiwan. Clin Exp Med. 2023;23(8):5327-36.
19. Chen NC, Chang H, Kao HW, Ou CW, Kuo MC, Wang PN, Lin TL, Wu JH, Hung YS, Su YJ, Ong YC, Shih HJ. Beta2-microglobulin is a valuable marker and identifies a poor-prognosis subgroup among intermediate-risk patients with diffuse large B cell lymphoma. Clin Exp Med. 2023;23(7):3759-66.
20. Kao HW, Kuo MC, Huang YJ, Chang H, Hu SF, Huang CF, Hung YS, Lin TL, Ou CW, Lien MY, Wu JH, Chen CC, Shih LY. Measurable Residual Disease Monitoring by Locked Nucleic Acid Quantitative Real-Time PCR Assay for IDH1/2 Mutation in Adult AML. Cancers (Basel). 2022;14(24).
21. Wang CW, Chi MH, Tsai TF, Yu KH, Kao HW, Chen HC, Chen CB, Lu CW, Chen WT, Chang YC, Chang CJ, Chang YT, Jan Wu YJ, Chang CJ, Huang YH, Ng CY, Huang PW, Lin YJ, Hui RC, Chung WH. Implementation of NUDT15 Genotyping to Prevent Azathioprine-Induced Leukopenia for Patients With Autoimmune Disorders in Chinese Population. Clin Pharmacol Ther. 2022;112(5):1079-87.
22. Tsai HJ, Hsiao HH, Hsu YT, Liu YC, Kao HW, Liu TC, Cho SF, Feng X, Johnston A, Bomalaski JS, Kuo MC, Chen TY. Phase I study of ADI-PEG20 plus low-dose cytarabine for the treatment of acute myeloid leukemia. Cancer Med. 2021;10(9):2946-55.
23. Ong YC, Kao HW, Chuang WY, Hung YS, Lin TL, Chang H, Kuo MC. Intravascular Large B-cell lymphoma: A case series and review of literatures. Biomed J. 2021;44(4):479-88.
24. Chuang WY, Chang ST, Yuan CT, Chang GJ, Chang H, Yeh CJ, Ueng SH, Kao HW, Wang TH, Wan YL, Shih LY, Chuang SS, Hsueh C. Identification of CD5/Cyclin D1 Double-negative Pleomorphic Mantle Cell Lymphoma: A Clinicopathologic, Genetic, and Gene Expression Study. Am J Surg Pathol. 2020;44(2):232-40.
25. Chou WC, Chang H, Wang PN, Kuo MC, Wu JH, Lin TL, Su YJ, Kao HW, Ou CW, Hung CY, Hsueh SW, Hung YS. Application of comprehensive geriatric assessment in predicting early mortality among elder patients with B-cell lymphoma receiving immunochemotherapy. Eur J Haematol. 2020;105(4):399-407.
26. Su YJ, Wang PN, Chang H, Shih LY, Lin TL, Kuo MC, Chuang WY, Wu JH, Tang TC, Hung YS, Dunn P, Kao HW*. Extranodal NK/T-cell lymphoma, nasal type: Clinical features, outcome, and prognostic factors in 101 cases. Eur J Haematol. 2018;101(3):379-88.
27. Huang YJ, Coustan-Smith E, Kao HW, Liu HC, Chen SH, Hsiao CC, Yang CP, Jaing TH, Yeh TC, Kuo MC, Lai CL, Chang CH, Campana D, Liang DC, Shih LY. Concordance of two approaches in monitoring of minimal residual disease in B-precursor acute lymphoblastic leukemia: Fusion transcripts and leukemia-associated immunophenotypes. J Formos Med Assoc. 2017;116(10):774-81.
28. Kao HW, Lin TL, Shih LY, Dunn P, Kuo MC, Hung YS, Wu JH, Tang TC, Chang H, Kuo TT, Ou CW, Wang PN. Clinical features, outcome and prognostic factors of 87 patients with angioimmunoblastic T cell lymphoma in Taiwan. Int J Hematol. 2016;104(2):256-65.
29. Lee MH, Lin YC, Cheng HT, Chuang WY, Huang HC, Kao HW. Coexistence of hepatoma with mantle cell lymphoma in a hepatitis B carrier. World J Gastroenterol. 2015;21(45):12981-6.
30. Kao HW, Liang DC, Kuo MC, Wu JH, Dunn P, Wang PN, Lin TL, Shih YS, Liang ST, Lin TH, Lai CY, Lin CH, Shih LY. High frequency of additional gene mutations in acute myeloid leukemia with MLL partial tandem duplication: DNMT3A mutation is associated with poor prognosis. Oncotarget. 2015;6(32):33217-25.
31. Lin TL, Nagata Y, Kao HW, Sanada M, Okuno Y, Huang CF, Liang DC, Kuo MC, Lai CL, Lee EH, Shih YS, Tanaka H, Shiraishi Y, Chiba K, Lin TH, Wu JH, Miyano S, Ogawa S, Shih LY. Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations. Haematologica. 2014;99(1):28-36.
32. Kao HW, Liang DC, Wu JH, Kuo MC, Wang PN, Yang CP, Shih YS, Lin TH, Huang YH, Shih LY. Gene mutation patterns in patients with minimally differentiated acute myeloid leukemia. Neoplasia. 2014;16(6):481-8.
33. Huang YM, Shih LY, Dunn P, Wang PN, Kuo MC, Wu JH, Lin TL, Tang TC, Chang H, Kao HW, Shih HJ, Hung YS. Chronic lymphocytic leukemia presenting with ascites diagnosed by clonality analysis via gene rearrangement assay: A case report. Oncol Lett. 2014;7(6):1911-4.
34. Kao HW, Sanada M, Liang DC, Lai CL, Lee EH, Kuo MC, Lin TL, Shih YS, Wu JH, Huang CF, Ogawa S, Shih LY. A high occurrence of acquisition and/or expansion of C-CBL mutant clones in the progression of high-risk myelodysplastic syndrome to acute myeloid leukemia. Neoplasia. 2011;13(11):1035-42.
35. Kao HW, Dunn P, Kuo MC, Shih LY, Lin TL, Wu JH, Tang TC, Chang H, Wu HC, Hung YS. Classical hairy cell leukemia and its variant: a 17-year retrospective survey in Taiwan Chinese. Acta Haematol. 2011;126(3):186-93.
